|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2007-9-27
|
|
pubmed:abstractText |
A critical factor in prostate cancer development and progression is the altered expression of apoptotic regulatory proteins which renders cells resistant to both hormone- and chemo-therapies. Resveratrol, a dietary component with chemopreventive properties has been reported to resensitize a variety of cancer cell types to apoptosis. In the current study, the ability of resveratrol pre-treatment to sensitize hormone refractory prostate cancer cell lines (PC-3 and DU145) to apoptosis and the mechanisms involved were investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-(4-morpholinyl)-8-phenyl-4H-1-benz...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/BIRC2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chromones,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Inhibitor of Apoptosis Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Morpholines,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Death Domain,
http://linkedlifedata.com/resource/pubmed/chemical/Stilbenes,
http://linkedlifedata.com/resource/pubmed/chemical/resveratrol
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0270-4137
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1641-53
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17823925-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17823925-Apoptosis,
pubmed-meshheading:17823925-Cell Line, Tumor,
pubmed-meshheading:17823925-Chromones,
pubmed-meshheading:17823925-Dose-Response Relationship, Drug,
pubmed-meshheading:17823925-Drug Combinations,
pubmed-meshheading:17823925-Enzyme Inhibitors,
pubmed-meshheading:17823925-Gene Silencing,
pubmed-meshheading:17823925-Humans,
pubmed-meshheading:17823925-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:17823925-Male,
pubmed-meshheading:17823925-Morpholines,
pubmed-meshheading:17823925-Phosphorylation,
pubmed-meshheading:17823925-Prostatic Neoplasms,
pubmed-meshheading:17823925-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:17823925-RNA, Small Interfering,
pubmed-meshheading:17823925-Receptors, Death Domain,
pubmed-meshheading:17823925-Signal Transduction,
pubmed-meshheading:17823925-Stilbenes
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms.
|
|
pubmed:affiliation |
UCD School of Medicine and Medical Sciences, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland. catherine.gill@ucd.ie
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
